ClinicalTrials.gg
Active, not recruitingNCT04975308EMBER-3Updated Jul 22, 2026Results posted

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

A Phase 3 interventional study of Imlunestrant and Exemestane in Breast Neoplasms and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Active, not recruiting at 243 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
874
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Enrollment
6th of 80
874 · median 138
Started
2021
with 3 others
Phase 3
16 of 88
1 open now
Primary completion
2024-06
later than 10 of 21 live
Registered
77th of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 6th largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 3, reaches primary completion later than 10 of the 21 other live ones, and was the 77th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.

03

Conditions studied

  • Breast Neoplasms
  • Neoplasm Metastasis

Keywords

  • SERD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of ER+, - locally advanced or breast cancer
  • Have disease that has demonstrated progression on or after an aromatase inhibitor alone or in combination with a cyclin-dependent kinase (CDK)4/6 inhibitor

    -- Participants are expected to have received prior treatment with a CDK4/6 inhibitor, if this treatment is approved and can be reimbursed

  • Must be deemed appropriate for treatment with endocrine therapy
  • If female, have a status by natural or surgical means or by ovarian function suppression
  • Have evaluable disease ( and/or nonmeasurable bone-only disease)
  • Have a performance status of 0 or 1 on the scale (Oken et al. 1982)
  • Have adequate renal, hematologic, and hepatic organ function
  • Must be able to swallow capsules/tablets

Exclusion criteria

Exclusion Criteria:

  • Have received prior treatment with chemotherapy (except for / adjuvant chemotherapy), fulvestrant, or any -ER-directed therapy (including SERDs and non-SERDs), any PI3K-, mTOR- or AKT- inhibitor
  • Have visceral crisis, lymphangitic spread within the lung, or any evidence of .
  • Have symptomatic or untreated .
  • Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study
  • Known allergic reaction against any of the components of the study treatment
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
874 participants (actual)

Study arms

  • Experimental
    Arm A: Imlunestrant

    Participants received Imlunestrant 400 milligrams (mg) orally once daily on days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation were met.

    Drug: Imlunestrant

  • Experimental
    Arm B: Investigator's Choice of Endocrine Therapy

    Participants received the investigator's choice of endocrine therapy, either exemestane 25 mg administered orally once daily on days 1 to 28 of a 28-day cycle, or Fulvestrant 500 mg intramuscularly on days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond, until disease progression or a criterion for discontinuation was met.

    Drug: Exemestane · Drug: Fulvestrant

  • Experimental
    Arm C: Imlunestrant + Abemaciclib

    Participants received Imlunestrant 400 mg orally once daily on Days 1 to 28 of a 28-day cycle, plus Abemaciclib 150 mg orally twice daily on Days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation was met.

    Drug: Imlunestrant · Drug: Abemaciclib

Interventions

06

What researchers measure

Primary outcomes

  1. Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)

    PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)

  2. Investigator-assessed PFS (Between Arm C and Arm A)

    PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)

  3. Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)

    PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)

Secondary outcomes

  1. Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm A and Arm B)

    PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)

  2. Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm C and Arm A)

    PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 25 months)

  3. Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm A and Arm B)

    ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

    Time frame: Randomization until measured progressive disease (up to 28 months)

  4. Investigator-assessed Duration of Response (DoR) (Between Arm A and Arm B)

    DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 26 Months)

  5. Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm A and Arm B)

    CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Randomization until measured progressive disease (up to 28 months)

  6. Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm C and Arm A)

    ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

    Time frame: Randomization until measured progressive disease (up to 26 months)

  7. Investigator-assessed Duration of Response (DoR) (Between Arm C and Arm A)

    DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 19 Months)

  8. Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm C and Arm A)

    CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Randomization until measured progressive disease (up to 26 months)

  9. Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm A and Arm B)

    Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing "no pain" and 10 representing "pain as bad as you can imagine." Participants not known to have sustained worsening will be censored at the last documented assessment.

    Time frame: Randomization through follow-up (up to 24 months)

  10. Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm C and Arm A)

    Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing "no pain" and 10 representing "pain as bad as you can imagine." Participants not known to have sustained worsening will be censored at the last documented assessment.

    Time frame: Randomization through follow-up (up to 20 months)

  11. Pharmacokinetics (PK): Plasma Concentration of Imlunestrant

    * Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing. * For Cycle 1 Day 1, sampling occurred at a "single" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.

    Time frame: Cycle 1 Day 1 (within 2 to 4 hours post-dose), Cycle 2 Day 1 (Predose), Cycle 3 Day 1 (3 hours post-dose, 5 hours post-dose), Cycle 4 Day 1 (Predose)

  12. Pharmacokinetics (PK): Plasma Concentration of Total Abemaciclib

    * Plasma concentration of total abemaciclib is the concentration of the parent abemaciclib and its metabolites in the plasma. * Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing. * For Cycle 1 Day 1, sampling occurred at a "single" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.

    Time frame: Cycle 1 Day 1 (within 2 to 4 hours post-dose), Cycle 2 Day 1 (Predose), Cycle 3 Day 1 (3 hours post-dose, 5 hours post-dose), Cycle 4 Day 1 (Predose)

  13. Overall Survival (OS) in the ITT Population

    OS in the ITT population

    Time frame: Randomization until death from any cause (estimated as up to 5 years)

  14. OS in the ESR1-mutation Detected Population

    OS in the ESR1-mutation detected population

    Time frame: Randomization until death from any cause (estimated as up to 5 years)

  15. Blinded Independent Review Committee (BIRC) Assessed PFS in the ESR1-Mutation Detected Population (Between Arm A and Arm B)

    PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)

  16. Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)

    ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

    Time frame: Randomization until measured progressive disease (up to 28 months)

  17. Investigator-assessed Duration of Response (DoR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)

    DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 24 Months)

  18. Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)

    CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Randomization until measured progressive disease (up to 28 months)

07

Results

Posted Jul 11, 2025

Participant flow

The study was initially planned with participants randomized 1:1 to either arm A or arm B. Following a protocol amendment, arm C was added later, after randomization to arms A and B had already begun.

Participant flow — Overall Study
MilestoneArm A: ImlunestrantArm B: Investigator's Choice of Endocrine TherapyArm C: Imlunestrant + Abemaciclib
Started331330213
Analysis population for the comparison between arm a and arm b3313300
Analysis population for the comparison between arm c and arm a2130213
Estrogen receptor 1 (esr1) mutation-detected population for comparison between arm a and arm b1381180
Received at least 1 dose of study drug326324209
Safety analysis population327324208
Completed246264117
Not completed856696
Withdrew: Withdrawal by subject6166
Withdrew: Physician decision031
Withdrew: Adverse event10112
Withdrew: On study treatment (ongoing)654375
Withdrew: Protocol deviation432

Outcome measures

PrimaryInvestigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)

PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Reported as:
Median · Months
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)
MonthsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)5.55 (5.32 to 7.26)5.52 (4.60 to 5.62)
Statistical analysis
  • Arm A: Imlunestrant vs Arm B: Investigator's Choice of Endocrine Therapy · Log Rank · p = 0.1158 · Hazard ratio (hr): 0.867 · 95% CI 0.724 to 1.039
PrimaryInvestigator-assessed PFS (Between Arm C and Arm A)

PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)
Reported as:
Median · Months
Investigator-assessed PFS (Between Arm C and Arm A)
MonthsArm C: Imlunestrant + AbemaciclibArm A: Imlunestrant
Investigator-assessed PFS (Between Arm C and Arm A)9.36 (7.49 to 11.86)5.49 (3.78 to 5.62)
Statistical analysis
  • Arm C: Imlunestrant + Abemaciclib vs Arm A: Imlunestrant · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.569 · 95% CI 0.441 to 0.733
PrimaryInvestigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)

PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Reported as:
Median · Months
Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)
MonthsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)5.49 (3.91 to 7.39)3.84 (3.68 to 5.52)
Statistical analysis
  • Arm A: Imlunestrant vs Arm B: Investigator's Choice of Endocrine Therapy · Log Rank · p = 0.0008 · Hazard ratio (hr): 0.617 · 95% CI 0.464 to 0.821
SecondaryBlinded Independent Review Committee (BIRC) Assessed PFS (Between Arm A and Arm B)

PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Reported as:
Median · Months
Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm A and Arm B)
MonthsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm A and Arm B)9.23 (7.33 to 11.07)7.36 (5.55 to 9.40)
SecondaryBlinded Independent Review Committee (BIRC) Assessed PFS (Between Arm C and Arm A)

PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
Randomization to the date of first documented progression of disease or death from any cause (up to 25 months)
Reported as:
Median · Months
Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm C and Arm A)
MonthsArm C: Imlunestrant + AbemaciclibArm A: Imlunestrant
Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm C and Arm A)14.52 (11.37 to NA)9.23 (5.49 to 13.70)
SecondaryPercentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm A and Arm B)

ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

Time frame:
Randomization until measured progressive disease (up to 28 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm A and Arm B)
Percentage of participantsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm A and Arm B)10.3 (7 to 13.5)6.4 (3.7 to 9)
SecondaryInvestigator-assessed Duration of Response (DoR) (Between Arm A and Arm B)

DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 26 Months)
Reported as:
Median · Months
Investigator-assessed Duration of Response (DoR) (Between Arm A and Arm B)
MonthsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Investigator-assessed Duration of Response (DoR) (Between Arm A and Arm B)11.10 (7.43 to 23.92)7.39 (5.59 to 15.67)
SecondaryPercentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm A and Arm B)

CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Randomization until measured progressive disease (up to 28 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm A and Arm B)
Percentage of participantsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm A and Arm B)46.8 (41.5 to 52.2)45.5 (40.1 to 50.8)
SecondaryPercentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm C and Arm A)

ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

Time frame:
Randomization until measured progressive disease (up to 26 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm C and Arm A)
Percentage of participantsArm C: Imlunestrant + AbemaciclibArm A: Imlunestrant
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm C and Arm A)21.1 (15.6 to 26.6)9.4 (5.5 to 13.3)
SecondaryInvestigator-assessed Duration of Response (DoR) (Between Arm C and Arm A)

DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 19 Months)
Reported as:
Median · Months
Investigator-assessed Duration of Response (DoR) (Between Arm C and Arm A)
MonthsArm C: Imlunestrant + AbemaciclibArm A: Imlunestrant
Investigator-assessed Duration of Response (DoR) (Between Arm C and Arm A)11.07 (9.13 to NA)10.02 (6.57 to 15.01)
SecondaryPercentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm C and Arm A)

CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Randomization until measured progressive disease (up to 26 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm C and Arm A)
Percentage of participantsArm C: Imlunestrant + AbemaciclibArm A: Imlunestrant
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm C and Arm A)62.9 (56.4 to 69.4)44.1 (37.5 to 50.8)
SecondaryTime to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm A and Arm B)

Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing "no pain" and 10 representing "pain as bad as you can imagine." Participants not known to have sustained worsening will be censored at the last documented assessment.

Time frame:
Randomization through follow-up (up to 24 months)
Reported as:
Median · Months
Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm A and Arm B)
MonthsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm A and Arm B)NA (NA to NA)NA (NA to NA)
SecondaryTime to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm C and Arm A)

Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing "no pain" and 10 representing "pain as bad as you can imagine." Participants not known to have sustained worsening will be censored at the last documented assessment.

Time frame:
Randomization through follow-up (up to 20 months)
Reported as:
Median · Months
Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm C and Arm A)
MonthsArm C: Imlunestrant + AbemaciclibArm A: Imlunestrant
Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm C and Arm A)NA (NA to NA)NA (NA to NA)
SecondaryPharmacokinetics (PK): Plasma Concentration of Imlunestrant

* Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing. * For Cycle 1 Day 1, sampling occurred at a "single" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.

Time frame:
Cycle 1 Day 1 (within 2 to 4 hours post-dose), Cycle 2 Day 1 (Predose), Cycle 3 Day 1 (3 hours post-dose, 5 hours post-dose), Cycle 4 Day 1 (Predose)
Reported as:
Geometric mean · nanograms per milliliter
Pharmacokinetics (PK): Plasma Concentration of Imlunestrant
nanograms per milliliterArm A: ImlunestrantArm C: Imlunestrant + Abemaciclib
Cycle 1 Day 1 (within 2 to 4 hours postdose)45.7 ± 12356.5 ± 122
Cycle 2 Day 1 (Predose)76 ± 7664.9 ± 103
Cycle 3 Day 1 (3 hours post-dose)141 ± 70144 ± 73
Cycle 3 Day 1 (5 hours post-dose)136 ± 69146 ± 69
Cycle 4 Day 1 (Predose)85.2 ± 6963 ± 97
SecondaryPharmacokinetics (PK): Plasma Concentration of Total Abemaciclib

* Plasma concentration of total abemaciclib is the concentration of the parent abemaciclib and its metabolites in the plasma. * Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing. * For Cycle 1 Day 1, sampling occurred at a "single" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.

Time frame:
Cycle 1 Day 1 (within 2 to 4 hours post-dose), Cycle 2 Day 1 (Predose), Cycle 3 Day 1 (3 hours post-dose, 5 hours post-dose), Cycle 4 Day 1 (Predose)
Reported as:
Geometric mean · nanograms per milliliter
Pharmacokinetics (PK): Plasma Concentration of Total Abemaciclib
nanograms per milliliterArm C: Imlunestrant + Abemaciclib
Cycle 1 Day 1 (within 2 to 4 hours postdose)158 ± 120
Cycle 2 Day 1 (Predose)792 ± 82
Cycle 3 Day 1 (3 hours post-dose)880 ± 74
Cycle 3 Day 1 (5 hours post-dose)926 ± 64
Cycle 4 Day 1 (Predose)783 ± 59
SecondaryOverall Survival (OS) in the ITT Population

OS in the ITT population

Time frame:
Randomization until death from any cause (estimated as up to 5 years)

Results for this outcome have not been posted.

SecondaryOS in the ESR1-mutation Detected Population

OS in the ESR1-mutation detected population

Time frame:
Randomization until death from any cause (estimated as up to 5 years)

Results for this outcome have not been posted.

SecondaryBlinded Independent Review Committee (BIRC) Assessed PFS in the ESR1-Mutation Detected Population (Between Arm A and Arm B)

PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Reported as:
Median · Months
Blinded Independent Review Committee (BIRC) Assessed PFS in the ESR1-Mutation Detected Population (Between Arm A and Arm B)
MonthsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Blinded Independent Review Committee (BIRC) Assessed PFS in the ESR1-Mutation Detected Population (Between Arm A and Arm B)7.43 (4.83 to 11.07)5.49 (3.84 to 6.70)
SecondaryPercentage of Participants With Investigator-assessed Objective Response Rate (ORR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)

ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

Time frame:
Randomization until measured progressive disease (up to 28 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)
Percentage of participantsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)11.6 (6.3 to 16.9)5.9 (1.7 to 10.2)
SecondaryInvestigator-assessed Duration of Response (DoR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)

DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 24 Months)
Reported as:
Median · Months
Investigator-assessed Duration of Response (DoR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)
MonthsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Investigator-assessed Duration of Response (DoR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)10.02 (3.98 to 14.59)5.59 (2.92 to 7.79)
SecondaryPercentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)

CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Randomization until measured progressive disease (up to 28 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)
Percentage of participantsArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)46.4 (38.1 to 54.7)36.4 (27.8 to 45.1)

Adverse events

Collected over Baseline up to 28 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Imlunestrant62/327 (19%)46/327 (14.1%)250/327 (76.5%)
Arm B: Investigator's Choice of Endocrine Therapy - Exemestane8/32 (25%)6/32 (18.8%)26/32 (81.3%)
Arm B: Investigator's Choice of Endocrine Therapy - Fulvestrant82/292 (28.1%)49/292 (16.8%)229/292 (78.4%)
Arm C: Imlunestrant + Abemaciclib36/208 (17.3%)42/208 (20.2%)203/208 (97.6%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy - ExemestaneArm B: Investigator's Choice of Endocrine Therapy - FulvestrantArm C: Imlunestrant + Abemaciclib
Cardiac arrestCardiac disorders1/3271/322/2920/208
General physical health deteriorationGeneral disorders0/3271/321/2920/208
Femoral neck fractureInjury, poisoning and procedural complications0/3271/320/2920/208
Tibia fractureInjury, poisoning and procedural complications0/3271/320/2920/208
Cerebellar infarctionNervous system disorders0/3271/320/2920/208
Neuropathy peripheralNervous system disorders0/3271/320/2920/208
Peripheral artery thrombosisVascular disorders0/3271/320/2920/208
PneumoniaInfections and infestations2/3270/323/2924/208
DiarrhoeaGastrointestinal disorders1/3270/320/2923/208
Pleural effusionRespiratory, thoracic and mediastinal disorders4/3270/320/2920/208
Most frequent other events
Showing 10 of 45
Most frequent other events
EventArm A: ImlunestrantArm B: Investigator's Choice of Endocrine Therapy - ExemestaneArm B: Investigator's Choice of Endocrine Therapy - FulvestrantArm C: Imlunestrant + Abemaciclib
DiarrhoeaGastrointestinal disorders71/3273/3237/292180/208
NauseaGastrointestinal disorders59/3274/3239/292104/208
AnaemiaBlood and lymphatic system disorders38/3278/3245/29291/208
VomitingGastrointestinal disorders31/3271/3215/29266/208
NeutropeniaBlood and lymphatic system disorders10/3270/325/29255/208
Neutrophil count decreasedInvestigations10/3270/3215/29247/208
FatigueGeneral disorders45/3272/3219/29246/208
Blood creatinine increasedInvestigations11/3271/327/29244/208
Aspartate aminotransferase increasedInvestigations47/3273/3246/29243/208
Decreased appetiteMetabolism and nutrition disorders26/3271/3214/29242/208

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)ImlunestrantInvestigator's Choice of Endocrine TherapyImlunestrant + AbemaciclibTotal
Mean60.4 ± 11.660.8 ± 12.061.9 ± 11.160.9 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)ImlunestrantInvestigator's Choice of Endocrine TherapyImlunestrant + AbemaciclibTotal
Female327329211867
Male4127
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ImlunestrantInvestigator's Choice of Endocrine TherapyImlunestrant + AbemaciclibTotal
Hispanic or Latino798037196
Not Hispanic or Latino218216148582
Unknown or Not Reported34342896
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ImlunestrantInvestigator's Choice of Endocrine TherapyImlunestrant + AbemaciclibTotal
American Indian or Alaska Native2316342
Asian929672260
Native Hawaiian or Other Pacific Islander0000
Black or African American117826
White186191111488
More than one race27312
Unknown or Not Reported17131646
Estrogen Receptor 1 (ESR1)-Mutation
Estrogen Receptor 1 (ESR1)-Mutation(Participants)ImlunestrantInvestigator's Choice of Endocrine TherapyImlunestrant + AbemaciclibTotal
Detected13811867323
Not detected193212146551
08

Study locations

243 sites

Showing the first 100 of 243 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, Garcia Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ruiz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard FC; EMBER-3 Study Group. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025 Mar 27;392(12):1189-1202. doi: 10.1056/NEJMoa2410858. Epub 2024 Dec 11. PubMed 39660834 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jun 2024, 32 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 32 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2021
First posted
Jul 23, 2021
StartActual
Oct 4, 2021
Primary completionActual
Jun 24, 2024
CompletionEst.
Aug 2027
Results first posted
Jul 11, 2025
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04975308
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Oct 4, 2021
Primary completion
Jun 24, 2024
Completion
Aug 2027 (estimated)
Results posted
Jul 11, 2025
Last update
Jul 22, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imlunestrant

Start the discussion